Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H25NO.ClH |
Molecular Weight | 283.837 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC[C@]1(CCN(C)C[C@H]1C)C2=CC(O)=CC=C2
InChI
InChIKey=GUSQVRBQQVKTMO-OALZAMAHSA-N
InChI=1S/C16H25NO.ClH/c1-4-8-16(9-10-17(3)12-13(16)2)14-6-5-7-15(18)11-14;/h5-7,11,13,18H,4,8-10,12H2,1-3H3;1H/t13-,16-;/m1./s1
Picenadol is a 4-phenylpiperidine derivative and a racemic mixture whose mixed agonist-antagonist properties are a consequence of the d-isomer being a potent opiate agonist, whereas the I-isomer is an opioid antagonist. In the mouse writhing and rat tail heat tests, the analgesic potency of picenadol is estimated to be 1/3 that of morphine. Picenadol itself has weak antagonist activity, whereas the antagonist potency of the l-isomer is approx. 1/10 that of nalorphine. Picenadol has high affinity for both the mu and delta receptors but a markedly lower affinity for the kappa receptor. Extensive pharmacological investigations show picenadol to have a low potential to produce opiate-like side effects, including a low liability for abuse and physical dependence. Antinociceptive properties of picenadol arise from mu agonist actions of the dextrorotatory isomer and that the levorotatory isomer acts to limit the efficacy of the racemate.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Preclinical pharmacology of Lilly compound LY150720, a unique 4-phenylpiperidine analgesic. | 1982 Apr |
|
Evaluation of the abuse potential of picenadol. | 1989 |
|
Disposition in humans of racemic picenadol, an opioid analgesic. | 1990 Nov-Dec |
|
Intramuscular picenadol in patients with postoperative pain. | 1993 Oct |
|
Picenadol in a large multicenter dental pain study. | 1994 Jan-Feb |
|
Absolute configurations and conformations of the opioid agonist and antagonist enantiomers of picenadol. | 1995 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12959314
Single dose - 50 mg
Route of Administration:
Intramuscular
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 15 15:14:35 GMT 2023 , Edited by admin on Fri Dec 15 15:14:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6917662
Created by
admin on Fri Dec 15 15:14:35 GMT 2023 , Edited by admin on Fri Dec 15 15:14:35 GMT 2023
|
PRIMARY | |||
|
C76852
Created by
admin on Fri Dec 15 15:14:35 GMT 2023 , Edited by admin on Fri Dec 15 15:14:35 GMT 2023
|
PRIMARY | |||
|
CHEMBL2220420
Created by
admin on Fri Dec 15 15:14:35 GMT 2023 , Edited by admin on Fri Dec 15 15:14:35 GMT 2023
|
PRIMARY | |||
|
29610N9WR1
Created by
admin on Fri Dec 15 15:14:35 GMT 2023 , Edited by admin on Fri Dec 15 15:14:35 GMT 2023
|
PRIMARY | |||
|
74685-16-8
Created by
admin on Fri Dec 15 15:14:35 GMT 2023 , Edited by admin on Fri Dec 15 15:14:35 GMT 2023
|
PRIMARY | |||
|
C035115
Created by
admin on Fri Dec 15 15:14:35 GMT 2023 , Edited by admin on Fri Dec 15 15:14:35 GMT 2023
|
PRIMARY | |||
|
DTXSID10225661
Created by
admin on Fri Dec 15 15:14:35 GMT 2023 , Edited by admin on Fri Dec 15 15:14:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD